The EU is stepping up real-time testing of potential Covid-19 vaccines.
Regulators are now looking at a shot made by U.S. giant Pfizer and German partner BioNTech.
That follows a similar announcement last week for a jab made by the UK’s AstraZeneca.
The move by the European Medicines Agency could speed up approval of new vaccines.
It allows researchers to submit findings as they go along, rather than waiting until trials are complete.
The Pfizer and BioNTech vaccine, along with AstraZeneca’s, are considered among the leading candidates for early approval.
Both have been in so-called ‘phase 3’ trials for several months.
That’s typically the final stage before getting the green light.
On Tuesday (October 6) the EMA said it now had the first batch of data on Pfizer’s offering, and would keep working until it had enough to make a final decision.
Earlier in the year, the drug remdesivir, made by U.S. firm Gilead, was conditionally approved using a similar process.